TICKERNERD
Menu
KAPAKAPAHealthcare · Biotechnology

KAPA Stock Forecast: Kairos Pharma Ltd. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$0.52
+2.95% on the day

The 2 Wall Street analysts covering Kairos Pharma Ltd. hold a median 12-month price target of $49 — +9325.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.7M
Ticker Nerd rank
35/ 100
Median analyst target
$49
Analysts covering
2
Revenue$0.0
Operating income−$1.4M
Net income−$1.4M
Free cash flow−$1.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.6%
1M
−66.7%
YTD
−89.5%
1Y
−91.4%
From 52W high
−92.3%
From 52W low
+9.7%
$0.47
$6.79
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KAPA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kairos Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
35/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Accruals
79
Growth
61
Revisions
47
Volatility
38
Issuance
36
Quality
33
Value
11
Momentum
3

Size (99): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KAPA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KAPA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$20.00$40.00$60.00$80.00Jan 26Apr 26Jul 26Oct 26KAPAHigh $84Median $49Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $14Median $49High $84

The green dot is the last close — the median target sits +9325.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2025D. Boral CapitalMaintainsBuy—
4 Nov 2025D. Boral CapitalMaintainsBuy—
20 Oct 2025D. Boral CapitalMaintainsBuy—
7 Oct 2025D. Boral CapitalMaintainsBuy—
19 Sept 2025D. Boral CapitalMaintainsBuy—
16 July 2025D. Boral CapitalMaintainsBuy—
4 June 2025D. Boral CapitalMaintainsBuy—
17 Apr 2025D. Boral CapitalMaintainsBuy—
3 Apr 2025HC Wainwright & Co.InitiatesBuy—
31 Mar 2025D. Boral CapitalMaintainsBuy—
27 Mar 2025Maxim GroupInitiatesBuy—
20 Mar 2025D. Boral CapitalMaintainsBuy—
26 Feb 2025D. Boral CapitalMaintainsBuy—
18 Feb 2025D. Boral CapitalMaintainsBuy—
12 Feb 2025D. Boral CapitalMaintainsBuy—
22 Jan 2025D. Boral CapitalMaintainsBuy—
14 Nov 2024D. Boral CapitalMaintainsBuy—
14 Oct 2024EF HuttonInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KAPA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KAPA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Kairos Pharma Ltd. returned −91.4% against +14.8% for the S&P 500, dividends included.

KAPA vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26KAPAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KAPA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Kairos Pharma Ltd. (KAPA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 85% of US stocks

EV / EBITDA
0.2×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−114.0%

Higher than 12% of US stocks

Return on assets
−66.9%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kairos Pharma Ltd. (KAPA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kairos Pharma Ltd. has a market value of $1.7M and an enterprise value of −$916K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$5.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$4.0M.

  • Shares outstanding: 21.4M.

  • Trailing P/E: −1.7×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Kairos Pharma Ltd. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

KAPA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KAPAKairos Pharma Ltd.$1.7M35
KPTIKaryopharm Therapeutics, Inc.$1.6M66
GOVXGeoVax Labs, Inc.$1.7M26
VRAXVirax Biolabs Group Ltd.$1.6M15
OGENOragenics, Inc.$1.6M10
GNPXGenprex, Inc.$1.8M12
ELABPMGC Holdings, Inc.$1.6M3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kairos Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KAPA news & analysis

Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development

Business Wire · 3 Nov 2026positive

Kairos Pharma President and CSO Neil Bhowmick presented on lead candidate ENV-105 and its interim efficacy results at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development, Cancer R&D 2026.

Why it matters — The presentation gives KAPA watchers an update on the company’s lead candidate and interim efficacy results.

CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma

Newsfile Corp · 22 Oct 2026positive

Newsfile reports that CEO.CA shared an Inside the Boardroom update featuring Kairos Pharma, with a headline stating that major U.S. cancer centers are testing a new drug. The supplied excerpt otherwise describes CEO.CA and does not provide details about the drug or testing.

Why it matters — KAPA watchers may note the headline’s claim about testing at major U.S. cancer centers, though the excerpt offers no supporting specifics.

Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer

Benzinga · 6 Oct 2026positive

Kairos Pharma announced interim efficacy results from its ongoing Phase 2 trial evaluating ENV-105 alongside apalutamide in patients with metastatic castration-resistant prostate cancer.

Why it matters — The update concerns clinical results for a Kairos Pharma drug candidate being tested in prostate cancer.

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

Business Wire · 6 Oct 2026positive

Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) combined with apalutamide in patients with metastatic castration-resistant prostate cancer. The interim analysis showed a statistically significant difference in progression-free survival.

Why it matters — The interim findings provide an update on a clinical-stage program being evaluated by Kairos Pharma.

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

Business Wire · 23 Sept 2026positive

Kairos Pharma announced that its President and Chief Scientific Officer, Neil Bhowmick, will present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference, held Sept. 28 to Oct. 1 at the Sheraton Boston Hotel, with sessions available on demand online.

Why it matters — A KAPA watcher would care because presenting and moderating at a major drug discovery conference raises the company's visibility within the industry.

FAQ

Frequently asked questions about KAPA stock

What is the KAPA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Kairos Pharma Ltd. have a median 12-month price target of $49, with estimates ranging from $14 to $84. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KAPA stock a buy right now?

Of the 2 analysts covering Kairos Pharma Ltd., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kairos Pharma Ltd. 35 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KAPA?

As at 4 Nov 2026, Kairos Pharma Ltd. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

Will KAPA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +9325.4% from the last close, and Ticker Nerd's factor model ranks Kairos Pharma Ltd. 35 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KAPA stock forecast for 2030?

No analyst covering Kairos Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KAPA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $84 over the next 12 months.

How has KAPA stock performed over the past year?

Kairos Pharma Ltd. returned -91.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kairos Pharma Ltd. do?

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics that address immune suppression and drug resistance.

What is the latest news on KAPA?

The most recent item we track (Business Wire, 3 Nov 2026): "Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development". Kairos Pharma President and CSO Neil Bhowmick presented on lead candidate ENV-105 and its interim efficacy results at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development, Cancer R&D 2026.

Company

About Kairos Pharma Ltd.

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics that address immune suppression and drug resistance. The company’s current portfolio centers on oncology candidates such as antibodies and small molecules designed to support immune function and target difficult-to-treat cancers, including prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma Ltd. also works on immunotherapy and cell therapy approaches, reflecting its emphasis on mechanisms that may help improve treatment response in cancer patients. Based in Los Angeles, California, the company operates in the biotechnology and pharmaceuticals sector, where it contributes to the development of experimental treatments intended for use in specialized oncology settings.

CEO Dr. John S. Yu M.D., Ph.D. · 1 employees · United States · https://kairospharma.com